London calling to the bio-world

One of the things I love most about the biotech business is that it is entirely global in nature. Chat with any CEO, even the head of a virtual group with 5 staffers and a single asset in Phase I, and you'll find some serious thoughts about U.S. vs European regulatory plans, an Asian strategy and a Japanese partnership. Drugs are global products, and our coverage of the industry reflects that.

So I'm particularly happy to be headed to London this weekend. The folks at One Nucleus were kind enough to offer me a chance to headline an event next Wednesday. It's called 'An Evening with John Carroll' and, despite using my name in the title, which I would have thought would be a sure kiss of death, we're evidently at the SRO stage on registrations. I'll also be meeting with a long list of biotech execs and scientists, with a stop at the House of Lords, something my Irish kin in Cork no doubt would find amusing.

Keeping with the international theme, I'm scheduled to return to New York to host a fireside chat with Tony Coles, the CEO at Onyx, on Feb. 12. Curiously, I find, New York and London are home to the two largest concentrations of FierceBiotech readers on the planet. Meaning we have more than a few people in the Big Pharma and investment world tracking what we have to say. For the next few days, I'll be paying attention to what some of those readers have to say.

In the meantime, if you have any suggestions on how we could improve our international coverage, drop me a line. Over the past 10 years FierceBiotech and the whole life sciences organization has been a work in progress. We're not stopping that now. -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.